BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34238111)

  • 21. Introducing novel potent anticancer agents of 1H-benzo[f]chromene scaffolds, targeting c-Src kinase enzyme with MDA-MB-231 cell line anti-invasion effect.
    Ahmed HEA; El-Nassag MAA; Hassan AH; Okasha RM; Ihmaid S; Fouda AM; Afifi TH; Aljuhani A; El-Agrody AM
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1074-1088. PubMed ID: 29923425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
    Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
    J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
    Arafa RK; Nour MS; El-Sayed NA
    Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
    ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors.
    Francini CM; Musumeci F; Fallacara AL; Botta L; Molinari A; Artusi R; Mennuni L; Angelucci A; Schenone S
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30227617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
    Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
    Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
    J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
    Li JR; Li DD; Fang F; Du QR; Lin L; Sun J; Qian Y; Zhu HL
    Org Biomol Chem; 2013 Dec; 11(48):8375-86. PubMed ID: 24178241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
    Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z
    Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
    Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
    Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
    J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
    Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
    J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
    Nourry A; Zambon A; Davies L; Niculescu-Duvaz I; Dijkstra HP; Ménard D; Gaulon C; Niculescu-Duvaz D; Suijkerbuijk BM; Friedlos F; Manne HA; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Mar; 53(5):1964-78. PubMed ID: 20148563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
    Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides.
    Yuan P; Gu X; Ni X; Qi Y; Shao X; Xu X; Liu J; Qian X
    Bioorg Med Chem Lett; 2021 Nov; 51():128371. PubMed ID: 34534673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
    Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.